Major Depressive Disorder Clinical Trial
Official title:
High Cortisol Levels as a Risk Factor for Depression in the Elderly and the Effect of Bright Light Treatment on Mood, Sleep-Wake Pattern and Self-Sufficiency
The purpose of this study is to investigate the following two hypotheses:
1. Treatment with bright light improves their sleep, mood, concentration and
self-sufficiency of elderly depressed subjects. This clinical improvement is
accompanied by decreases in cortisol/DHEA ratio and increases in melatonin
concentration in urine and saliva.
2. The eventual beneficial effect of bright light treatment can be predicted by the
presence of sleep-wake rhythm disturbances as found using muscle activity registration,
and by cortisol/DHEA and melatonin concentrations in saliva and urine over the day and
the night.
Background: Depression frequently occurs in the elderly. In normal aging, and in depression,
the functioning of the suprachiasmatic nucleus (SCN) is impaired, as evidenced by an
increased prevalence of day-night rhythm perturbations, e.g. sleeping disorders. Also, the
normal inhibition of SCN neurons on corticotrophin-releasing hormone (CRH) producing cells
is decreased, which could be responsible for the hyperactive hypothalamus-pituitary
adrenocortical axis (HPA-axis). This raises the question whether elderly patients with
depression have more impaired SCN activity and whether HPA-activity is enhanced. Using
bright light therapy (BLT) the SCN can be stimulated. And, the beneficial effects of BLT on
seasonal depressive disorders are well accepted. Nevertheless, the effects of BLT in aged
depressed patients have never been studied, as yet.
Aims: The aim of this study is to test the hypothesis that BLT improves sleep, mood,
concentration and self-efficacy of older people with depression and this improvement is
accompanied by a normalization of HPA-indices.
Methods: Randomised double blind placebo controlled trial in 120 subjects of 60 years and
older with a diagnosis of major depressive disorder (DSM-IV/SCID-I). Subjects are recruited
through referrals of psychiatric outpatient clinics and from case-finding from databases of
general practitioners and old-people homes in the Amsterdam region. After inclusion subjects
are randomly allocated to bright blue light vs. dim red light groups using two Philips
Bright Light Energy boxes type HF 3304 per subject from which the light bulbs have been
covered with bright blue or dim red light permitting filters. Criteria for stratification
are the use of SSRIs. Prior to treatment a 1-week run-in period without treatment will be
used as a baseline condition. At three time points several endocrinological,
psychophysiological, psychometrically, neuropsychological, and neuroimaging measures are
performed: just before start of light therapy (T0), after completion of the three week light
therapy period (T1), and three weeks thereafter (T2).
Relevance: This study is designed to show whether light therapy can reduce depressive
symptoms of elderly patients with a major depressive disorder. If this is the case, then
additional lightning may easily be installed in the homes of patients to serve as a
maintenance treatment. Also, if our data support the role of a dysfunctional biological
clock in depressed elderly subjects, such a finding may guide the further development of
drugs that inhibit the HPA axis.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |